The macroscopic and microscopic pharmacology of monoclonal antibodies
- PMID: 1618598
- DOI: 10.1016/0192-0561(92)90176-l
The macroscopic and microscopic pharmacology of monoclonal antibodies
Abstract
When monoclonal antibodies directed against tumor-associated antigens are injected intravenously, they sometimes fail to distribute uniformly in the substance of a tumor. To understand the possible reasons, it is necessary to consider both macroscopic and microscopic features of the pharmacology. We have analyzed antibody penetration into microscopic primary tumors and metastases by melding together information on the global pharmacokinetics, convective and diffusive transport across the blood capillary wall, diffusion through the tumor interstitial space, antigen - antibody interaction, metabolism, and lymphatic outflow. This analysis predicts that the very fact of successful binding will decrease the homogeneity of distribution. We believe that this "binding site barrier" constitutes major challenges to the molecular design of next-generation antibodies and also to the design of many other types of ligands for use in treatment of solid tumors.
Similar articles
-
A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.J Nucl Med. 1990 Jul;31(7):1191-8. J Nucl Med. 1990. PMID: 2362198
-
An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier".Cancer Res. 1991 Sep 15;51(18):4776-84. Cancer Res. 1991. PMID: 1893370
-
Heterogeneity of monoclonal antibody distribution and radiation dose in tumors: a modeling analysis.Hokkaido Igaku Zasshi. 1991 May;66(3):369-84. Hokkaido Igaku Zasshi. 1991. PMID: 1885162
-
Affinity and avidity in antibody-based tumor targeting.Cancer Biother Radiopharm. 2009 Apr;24(2):155-61. doi: 10.1089/cbr.2009.0627. Cancer Biother Radiopharm. 2009. PMID: 19409036 Free PMC article. Review.
-
Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier".Cancer Res. 1992 May 1;52(9 Suppl):2747s-2751s. Cancer Res. 1992. PMID: 1563006 Review.
Cited by
-
Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys.MAbs. 2013 Sep-Oct;5(5):776-86. doi: 10.4161/mabs.25642. Epub 2013 Jul 8. MAbs. 2013. PMID: 23924796 Free PMC article.
-
Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy.Leuk Res. 2009 Sep;33(9):1233-42. doi: 10.1016/j.leukres.2009.02.006. Epub 2009 Mar 26. Leuk Res. 2009. PMID: 19327829 Free PMC article.
-
Endogenous antibodies for tumor detection.Sci Rep. 2014 May 30;4:5088. doi: 10.1038/srep05088. Sci Rep. 2014. PMID: 24875800 Free PMC article.
-
Key Physicochemical Characteristics Influencing ADME Properties of Therapeutic Proteins.Adv Exp Med Biol. 2019;1148:115-129. doi: 10.1007/978-981-13-7709-9_6. Adv Exp Med Biol. 2019. PMID: 31482497 Review.
-
Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model.Theranostics. 2013 Apr 23;3(6):357-65. doi: 10.7150/thno.5908. Print 2013. Theranostics. 2013. PMID: 23781283 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources